Distinct dynamics of mRNA LNPs in mice and nonhuman primates revealed by in vivo imaging.
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
20 Jun 2024
20 Jun 2024
Historique:
received:
07
12
2023
accepted:
03
06
2024
medline:
21
6
2024
pubmed:
21
6
2024
entrez:
20
6
2024
Statut:
epublish
Résumé
The characterization of vaccine distribution to relevant tissues after in vivo administration is critical to understanding their mechanisms of action. Vaccines based on mRNA lipid nanoparticles (LNPs) are now being widely considered against infectious diseases and cancer. Here, we used in vivo imaging approaches to compare the trafficking of two LNP formulations encapsulating mRNA following intramuscular administration: DLin-MC3-DMA (MC3) and the recently developed DOG-IM4. The mRNA formulated in DOG-IM4 LNPs persisted at the injection site, whereas mRNA formulated in MC3 LNPs rapidly migrated to the draining lymph nodes. Furthermore, MC3 LNPs induced the fastest increase in blood neutrophil counts after injection and greater inflammation, as shown by IL-1RA, IL-15, CCL-1, and IL-6 concentrations in nonhuman primate sera. These observations highlight the influence of the nature of the LNP on mRNA vaccine distribution and early immune responses.
Identifiants
pubmed: 38902327
doi: 10.1038/s41541-024-00900-5
pii: 10.1038/s41541-024-00900-5
doi:
Types de publication
Journal Article
Langues
eng
Pagination
113Informations de copyright
© 2024. The Author(s).
Références
Pardi, N., Hogan, M. J., Porter, F. W. & Weissman, D. mRNA vaccines—a new era in vaccinology. Nat. Rev. Drug Discov. 17, 261–279 (2018).
doi: 10.1038/nrd.2017.243
pubmed: 29326426
pmcid: 5906799
Jackson, L. A. et al. An mRNA vaccine against SARS-CoV-2—preliminary report. N. Engl. J. Med. 383, 1920–1931 (2020).
doi: 10.1056/NEJMoa2022483
pubmed: 32663912
Baden, L. R. et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N. Engl. J. Med. 384, 403–416 (2021).
doi: 10.1056/NEJMoa2035389
pubmed: 33378609
Verbeke, R., Lentacker, I., De Smedt, S. C. & Dewitte, H. The dawn of mRNA vaccines: the COVID-19 case. J. Control Release 333, 511–520 (2021).
doi: 10.1016/j.jconrel.2021.03.043
pubmed: 33798667
pmcid: 8008785
Buschmann, M. D. et al. Nanomaterial delivery systems for mRNA Vaccines. Vaccines 9 (2021).
Jackson, N. A. C., Kester, K. E., Casimiro, D., Gurunathan, S. & DeRosa, F. The promise of mRNA vaccines: a biotech and industrial perspective. NPJ Vaccines 5, 11 (2020).
doi: 10.1038/s41541-020-0159-8
pubmed: 32047656
pmcid: 7000814
Sabnis, S. et al. A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates. Mol. Ther. 26, 1509–1519 (2018).
doi: 10.1016/j.ymthe.2018.03.010
pubmed: 29653760
pmcid: 5986714
Carrasco, M. J. et al. Ionization and structural properties of mRNA lipid nanoparticles influence expression in intramuscular and intravascular administration. Commun. Biol. 4, 956 (2021).
doi: 10.1038/s42003-021-02441-2
pubmed: 34381159
pmcid: 8358000
Alameh, M. G. et al. Lipid nanoparticles enhance the efficacy of mRNA and protein subunit vaccines by inducing robust T follicular helper cell and humoral responses. Immunity 54, 2877–2892.e2877 (2021).
doi: 10.1016/j.immuni.2021.11.001
pubmed: 34852217
pmcid: 8566475
Rizk, M. & Tuzmen, S. Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran. Pharmgenom. Pers. Med 10, 267–278 (2017).
Akinc, A. et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat. Nanotechnol. 14, 1084–1087 (2019).
doi: 10.1038/s41565-019-0591-y
pubmed: 31802031
Ripoll, M. et al. An imidazole-modified lipid confers enhanced mRNA-LNP stability and strong immunization properties in mice and non-human primates. Biomaterials 286, 121570 (2022).
doi: 10.1016/j.biomaterials.2022.121570
pubmed: 35576809
pmcid: 9078044
Bernard, M. C. et al. The impact of nucleoside base modification in mRNA vaccine is influenced by the chemistry of its lipid nanoparticle delivery system. Mol. Ther. Nucleic Acids 32, 794–806 (2023).
doi: 10.1016/j.omtn.2023.05.004
pubmed: 37346973
pmcid: 10280092
Van Tilbeurgh, M. et al. Predictive markers of immunogenicity and efficacy for human vaccines. Vaccines 9, 579 (2021).
doi: 10.3390/vaccines9060579
pubmed: 34205932
pmcid: 8226531
McCarthy, C. E., White, J. M., Viola, N. T. & Gibson, H. M. In vivo Imaging technologies to monitor the immune system. Front. Immunol. 11, 1067 (2020).
doi: 10.3389/fimmu.2020.01067
pubmed: 32582173
pmcid: 7280489
Rashidian, M. et al. Noninvasive imaging of immune responses. Proc. Natl Acad. Sci. USA 112, 6146–6151 (2015).
doi: 10.1073/pnas.1502609112
pubmed: 25902531
pmcid: 4434737
Todorova, B. et al. Electroporation as a vaccine delivery system and a natural adjuvant to intradermal administration of plasmid DNA in macaques. Sci. Rep. 7, 4122 (2017).
doi: 10.1038/s41598-017-04547-2
pubmed: 28646234
pmcid: 5482824
Todorova, B. et al. Fibered confocal fluorescence microscopy for the noninvasive imaging of langerhans cells in Macaques. Contrast Media Mol Imaging 2017, 3127908 (2017).
doi: 10.1155/2017/3127908
pubmed: 29097915
pmcid: 5612736
Salabert, N. et al. Intradermal injection of an anti-Langerin-HIVGag fusion vaccine targets epidermal Langerhans cells in nonhuman primates and can be tracked in vivo. Eur. J. Immunol. 46, 689–700 (2016).
doi: 10.1002/eji.201545465
pubmed: 26678013
Romain, G. et al. CD34-derived dendritic cells transfected ex vivo with HIV-Gag mRNA induce polyfunctional T-cell responses in nonhuman primates. Eur. J. Immunol. 42, 2019–2030 (2012).
doi: 10.1002/eji.201242478
pubmed: 22585548
pmcid: 3649569
Pardi, N. et al. Expression kinetics of nucleoside-modified mRNA delivered in lipid nanoparticles to mice by various routes. J. Control Release 217, 345–351 (2015).
doi: 10.1016/j.jconrel.2015.08.007
pubmed: 26264835
pmcid: 4624045
Qiu, M. et al. Lung-selective mRNA delivery of synthetic lipid nanoparticles for the treatment of pulmonary lymphangioleiomyomatosis. Proc. Natl Acad. Sci. USA 119, e2116271119 (2022).
doi: 10.1073/pnas.2116271119
pubmed: 35173043
pmcid: 8872770
Lindsay, K. E. et al. Visualization of early events in mRNA vaccine delivery in non-human primates via PET-CT and near-infrared imaging. Nat. Biomed. Eng. 3, 371–380 (2019).
doi: 10.1038/s41551-019-0378-3
pubmed: 30936432
Rosenbaum, P. et al. Molecular and cellular dynamics in the skin, the lymph nodes, and the blood of the immune response to intradermal injection of modified vaccinia Ankara vaccine. Front. Immunol. 9, 870 (2018).
doi: 10.3389/fimmu.2018.00870
pubmed: 29922280
pmcid: 5996922
Vogel, A. B. et al. BNT162b vaccines protect rhesus macaques from SARS-CoV-2. Nature 592, 283–289 (2021).
doi: 10.1038/s41586-021-03275-y
pubmed: 33524990
Corbett, K. S. et al. Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. N. Engl. J. Med. 383, 1544–1555 (2020).
doi: 10.1056/NEJMoa2024671
pubmed: 32722908
Liang, F. et al. Efficient targeting and activation of antigen-presenting cells in vivo after modified mRNA vaccine administration in rhesus macaques. Mol. Ther. 25, 2635–2647 (2017).
doi: 10.1016/j.ymthe.2017.08.006
pubmed: 28958578
pmcid: 5768558
Bachmann, M. F. & Jennings, G. T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10, 787–796 (2010).
doi: 10.1038/nri2868
pubmed: 20948547
Thomas, S. N., Rohner, N. A. & Edwards, E. E. Implications of lymphatic transport to lymph nodes in immunity and immunotherapy. Annu. Rev. Biomed. Eng. 18, 207–233 (2016).
doi: 10.1146/annurev-bioeng-101515-014413
pubmed: 26928210
pmcid: 5518935
Hassett, K. J. et al. Impact of lipid nanoparticle size on mRNA vaccine immunogenicity. J. Control Release 335, 237–246 (2021).
doi: 10.1016/j.jconrel.2021.05.021
pubmed: 34019945
Lu, L., Li, J., Moussaoui, M. & Boix, E. Immune modulation by human secreted RNases at the extracellular space. Front. Immunol. 9, 1012 (2018).
doi: 10.3389/fimmu.2018.01012
pubmed: 29867984
pmcid: 5964141
Cao, Y. & Gao, G. F. mRNA vaccines: a matter of delivery. EClinicalMedicine 32, 100746 (2021).
doi: 10.1016/j.eclinm.2021.100746
pubmed: 33644722
pmcid: 7889829
Bahl, K. et al. Preclinical and clinical demonstration of immunogenicity by mRNA Vaccines against H10N8 and H7N9 influenza viruses. Mol. Ther. 25, 1316–1327 (2017).
doi: 10.1016/j.ymthe.2017.03.035
pubmed: 28457665
pmcid: 5475249
Hassett, K. J. et al. Optimization of lipid nanoparticles for intramuscular administration of mRNA vaccines. Mol. Ther. Nucleic Acids 15, 1–11 (2019).
doi: 10.1016/j.omtn.2019.01.013
pubmed: 30785039
pmcid: 6383180
Ndeupen, S. et al. The mRNA-LNP platform’s lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory. iScience 24, 103479 (2021).
doi: 10.1016/j.isci.2021.103479
pubmed: 34841223
pmcid: 8604799
Moghimi, S. M. & Simberg, D. Pro-inflammatory concerns with lipid nanoparticles. Mol. Ther. 30, 2109–2110 (2022).
doi: 10.1016/j.ymthe.2022.04.011
pubmed: 35487214
pmcid: 9047613
Tahtinen, S. et al. IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines. Nat. Immunol. 23, 532–542 (2022).
doi: 10.1038/s41590-022-01160-y
pubmed: 35332327
Verbeke, R., Hogan, M. J., Lore, K. & Pardi, N. Innate immune mechanisms of mRNA vaccines. Immunity 55, 1993–2005 (2022).
doi: 10.1016/j.immuni.2022.10.014
pubmed: 36351374
pmcid: 9641982
Chivukula, S. et al. Development of multivalent mRNA vaccine candidates for seasonal or pandemic influenza. NPJ Vaccines 6, 153 (2021).
doi: 10.1038/s41541-021-00420-6
pubmed: 34916519
pmcid: 8677760
Cheng, M. H. Y. et al. Induction of Bleb structures in lipid nanoparticle formulations of mRNA leads to improved transfection potency. Adv. Mater. 35, e2303370 (2023).
doi: 10.1002/adma.202303370
pubmed: 37172950
Baladi, T. et al. Stealth fluorescence labeling for live microscopy imaging of mRNA Delivery. J. Am. Chem. Soc. 143, 5413–5424 (2021).
doi: 10.1021/jacs.1c00014
pubmed: 33797236
pmcid: 8154517